Theratechnologies Inc T.TH

Great

[scarlet1967]

In case you did not receive this already, please see below for information on an upcoming investor event highlighting our SORT1+ Technology, featuring key opinion leader Dr. Richard Beliveau, taking place on Monday, June 21, 2021 at 11:00am ET. 

The webinar will feature a presentation by Key Opinion Leader (KOL) Richard Bliveau, Ph.D. (Universit du Qubec Montral) who will discuss the science of receptor-mediated cancer therapy and the discovery of sortilin as a novel target in cancer treatment. Dr. Bliveau will be available to answer questions following the formal presentations.

 

Theratechnologies' management team will also give an update on their oncology pipeline including TH1902, the Company's lead investigational peptide-drug conjugate (PDC) stemming from its SORT1+ Technology™ in oncology. SORT1+ Technology is a new class of cancer treatment targeting all sortilin-expressing cancers by linking approved anticancer drugs to a proprietary peptide that specifically binds to the sortilin receptor. The PDC is internalized by the sortilin receptor and the therapeutic agent is released directly inside the cancer cell. TH1902 was granted fast track designation by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy and is currently being evaluated in a Phase 1 clinical trial.

 

[Bucknelly21]

I got mine this morning 

[SPCEO1]

Excellent news! TH continues to lead with cancer versus NASH which likely indicates things are following an encouraging path so far in the cancer phase I trial.

[scarlet1967]

I agree I also wonder what that update will be?Any trial process specific information? Wishful thinking?

[scarlet1967]

This is what LSA does, would they approach retail investors? Will we get that report soon after the webinar? "LifeSci Advisors’ Approach   LifeSci Advisors employs a “client as partner” approach to our company relationships. From the beginning of each client relationship, we immerse ourselves in the subject matter and work closely with the client to develop an

[Bucknelly21]

scarlett sent you a message in your inbox check it out 

[qwerty22]

That's quite a long lead time into the event. Maybe it's timed to catch him before he goes off to the cottage for a month. But like you it's the management update that caught my attention. Let's hope they have something to say.

[Wino115]

Keep it coming THTX/LSA.  Information to aid in evaluating the company's pipeline is crucial.  There's a button to send in questinos prior to the event.  We should think about the most important issues for the whole SORT1+ and the Phase 1 trial and submit them.  Better to get the best questions in so they are answered and not innundate them with too many.  

[scarlet1967]

I did submit some questions, I find it odd that they didn't issue a PR or posting the news on their social media platforms!

[qwerty22]

18 days to go

[SPCEO1]

Plenty of time to formulate questions, so no need to rush on that Scarlett. Also, it is concievable that the date was picked because there will be nformation announced on new cancer reserach THTX has completed before then. If so, that might change the questions you want to submit so putting questions in too soon may be unproductive.  THTX is trying to rebrand the stock. It is a big job and

[scarlet1967]

My questions wasn't really related to the science or the trial itself as I am sure they will address both, as  a big fan of marketing  the programs by giving some insights re the financial opportunities of the protocol although this is more of the KOL's opinion about the drug I want someone on the webinar for instance if CEO or CMO are present to shed some light on the financial

[SPCEO1]

I am quite curious to see what LSA's report looks like. It may be too early for them to start talking about the market opportunity for TH-1902 in anything other than broad strokes. But maybe not. Hopefully, we will soon see.  Perhaps the LSA report will come out prior to 6/21. 

[qwerty22]

I'm with you. It seems to me highly likely the program will change quite radically after the Ph1 data so that details on the market might quickly become irrelevant. I know you've talked about an LSA report before, did Paul say there would be a public report published? I missed that.

[SPCEO1]

No, the company has said nothing about a report being published by LSA as far as I am aware of, but that is just what LSA does. I have gotten their research for a while now and they typically produce a report. I would be really surprised if they did not do so in TH's case as TH really, really needs some decent research coverage which looks beyond  the past commercial failings and instead

[Lee430]

Hooray!!  The Great Rebrand or Thera 2.0 begins :->

[SPCEO1]

I suspect the reason for that is the company knows we who follow the company closely are anxious for LSA to get going and thus they alerted us to the 6/21 meeting earlier than what normally would be the case. And they are aware that the way the September announcement of the move to general NASH was handled (no build-up of expectations before hand) meant that few actually heard the news. I am on